A phase II, open‐label evaluation of cysteamine tolerability in patients with Huntington's disease

E-ISSN： 1531-8257|30|2|288-289

ISSN： 0885-3185

Source： MOVEMENT DISORDERS, Vol.30, Iss.2, 2015-02, pp. : 288-289

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

High‐dose transdermal nicotine in Parkinson's disease patients: a randomized, open‐label, blinded‐endpoint evaluation phase 2 study

EUROPEAN JOURNAL OF NEUROLOGY, Vol. 25, Iss. 1, 2018-01 ,pp. : 120-127

John Wiley & Sons Inc

Access to resources Recommend Favorite

CCH Phase 3 Open‐Label Study

THE JOURNAL OF SEXUAL MEDICINE, Vol. 12, Iss. 1, 2015-01 ,pp. : 248-258

John Wiley & Sons Inc

Access to resources Recommend Favorite

An open-label evaluation of rifaximin in the treatment of active Crohn's disease

By Shafran Ira Johnson Lorin K.

Current Medical Research and Opinion, Vol. 21, Iss. 8, 2005-08 ,pp. : 1165-1170

Informa Healthcare

Access to resources Recommend Favorite

An Open-Label, Noncomparative Phase II Trial to Evaluate the Efficacy and Safety of Docetaxel in Combination with Gefitinib in Patients with Hormone-Refractory Metastatic Prostate Cancer

Oncology Research and Treatment, Vol. 30, Iss. 7, 2007-06 ,pp. : 355-360

Karger

Access to resources Recommend Favorite

Results of a phase I/II open‐label, safety and efficacy trial of coagulation factor IX (recombinant), albumin fusion protein in haemophilia B patients

HAEMOPHILIA, Vol. 21, Iss. 6, 2015-11 ,pp. : 784-790

John Wiley & Sons Inc

Access to resources Recommend Favorite